Merck Profit Rises on Strong Keytruda Demand

Core Insights - Merck reported an increase in third-quarter profit and raised its full-year outlook due to the growing demand for its Keytruda cancer drug [1] Financial Performance - The company experienced higher profits in the third quarter, indicating strong financial health and operational efficiency [1] - The full-year outlook has been boosted, reflecting confidence in continued revenue growth driven by Keytruda [1] Product Demand - Demand for Keytruda, Merck's flagship cancer drug, continues to rise, contributing significantly to the company's revenue growth [1]